Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Rodríguez Moncalvo (Buenos Aires, Argentina), J. Malet Ruiz (Buenos Aires, Argentina), M. Mastroianni (Buenos Aires, Argentina), M. Khoury (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina). Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?. 4703

Member's Comments

No comment yet.

Related content which might interest you: Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017 Year: 2018 Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) – modelling the myth Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Challenges in idiopathic pulmonary fibrosis trials: the point on end-points Source: Eur Respir Rev 2011; 20: 195-200 Year: 2011 Forced vital capacity decreases rapidly in patients with idiopathic upper lobe-dominant pulmonary fibrosis Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 830-836 Year: 2010 Exercise capacity in idiopathic pulmonary fibrosis and COPD Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Early decrease of forced vital capacity is a good prediction tool for prognosis in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Serologically assessed elastin degradation is related to force vital capacity in patients with IPF Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Ventilatory efficiency and exercise capacity during exercise in the patients with idiopathic pulmonary fibros Source: International Congress 2014 – Alterations of exercise and lung function in different diseases Year: 2014 Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis (IPF) with inspiratory muscle training Source: Annual Congress 2007 - Assessment and outcomes in non-COPD patients Year: 2007 Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis Source: Eur Respir J 2012; 40: 61-66 Year: 2012 Evaluation of bronchodilator responses in patients with "irreversible" emphysema Source: Eur Respir J 2001; 18: 914-920 Year: 2001 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016